EM1710H "Actionable Tumor Genomics: Ready for Cancer Care & Clinical Trials?" (IM GR-102717)

To discuss the role of genomic profiling of tumors in identifying tumor vulnerabilities that inform cancer treatment and/or enrollment in clinical trials with targeted therapies.

Target Audience

UT Southwestern faculty, fellows, residents and medical students, community physicians, nurse clinicians, physician assistants and nurses.

Learning Objectives

At the conclusion of this activity, the participant should be able to:

  • Understand the role of next gen sequencing in drug development
  • Understand there is a variety of mechanism of acquired drug resistance to targeted therapies that can be identified by tumor genomic profiling
  • Understand the role of plasma tumor cell-free DNA sequencing in clinical investigation
Course summary
Available credit: 
  • 1.00 AMA
Course opens: 
11/01/2017
Course expires: 
12/01/2017
Cost:
$0.00
Part of: 
123 Internal Medicine Grand Rounds: Online 2017

Photo: Carlos L. Arteaga, M.D.Carlos L. Arteaga, M.D.
Professor of Internal Medicine
Director, Harold C. Simmons Comprehensive Cancer Center
The Lisa K. Simmons Distinguished Chair in Comprehensive Oncology
Associate Dean of Oncology Programs
Pamela Hearn Isom Visiting Professor

Available Credit

  • 1.00 AMA

Price

Cost:
$0.00
Please login or create an account to take this course.

Required Hardware/software

Activities should be run with recent versions of common browsers, including Internet Explorer, Firefox and Google Chrome